Clinical Trials Logo

Sarcoma clinical trials

View clinical trials related to Sarcoma.

Filter by:

NCT ID: NCT02873923 Completed - Cancer Clinical Trials

Variability of Definitions for Survival Endpoints and Surrogate Properties for OS in Sarcoma Trials: a Meta-analysis

DATECAN-2
Start date: October 2012
Phase:
Study type: Observational

The DATECAN-2 project aims at assessing the surrogate properties for OS of several time-to-event endpoints through meta-analyses of completed and published randomized controlled trials. Two main cancer localization are concerned: breast cancer and soft-tissue sarcomas. The impact of survival endpoints' definitions on the trials' results and conclusions will also be evaluated.

NCT ID: NCT02849366 Completed - Clinical trials for Recurrent Adult Soft Tissue Sarcoma

Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma

Start date: July 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent sarcoma.

NCT ID: NCT02833246 Completed - Sarcoma Clinical Trials

Using a Patient-Centered mHealth Intervention to Improve Adherence to Oral Anticancer Medications

Start date: June 28, 2016
Phase: N/A
Study type: Interventional

This study is being done to determine if sending reminder text messages helps patients take their Oral Anticancer Medication (OAMs) when they are supposed to.

NCT ID: NCT02815995 Completed - Clinical trials for Advanced and/or Metastatic Sarcoma

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Start date: August 16, 2016
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if the combination of durvalumab and tremelimumab can help to control sarcoma. The safety of this drug combination will also be studied. This is an investigational study. Durvalumab and tremelimumab are not FDA approved or commercially available. They are currently being used for research purposes only. The study doctor can explain how the study drugs are designed to work. Up to 150 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT02805725 Completed - Clinical trials for Soft-tissue Sarcomas

Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide

TARMIC
Start date: December 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Assessment of the efficacy and safety of trabectedin and metronomic cyclophosphamide (CP) in patients with advanced pretreated soft-tissue sarcomas, once the Maximum Tolerated Dose (MTD) have been determined (phase I trial).

NCT ID: NCT02793050 Completed - Clinical trials for Sarcoma, Soft Tissue

Retrospective Study of Trabectedin in Soft Tissue Sarcomas

TrObs
Start date: June 15, 2016
Phase:
Study type: Observational

This is an independent, observational, retrospective post marketing study on the use of trabectedin in a clinical setting. A data collection on the clinical use of the drug will help to improve knowledge and might contribute to optimize the clinical use of the drug.

NCT ID: NCT02787642 Completed - Soft-tissue Sarcoma Clinical Trials

A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma

RADIOSARP
Start date: January 2016
Phase: Phase 1
Study type: Interventional

A phase Ib study of Olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma.

NCT ID: NCT02784795 Completed - Breast Cancer Clinical Trials

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Start date: November 4, 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.

NCT ID: NCT02783599 Completed - Soft Tissue Sarcoma Clinical Trials

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Start date: October 11, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).

NCT ID: NCT02748135 Completed - Clinical trials for Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

Start date: May 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.